Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Scagliotti GV, et al. Among authors: vansteenkiste j. J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27. J Clin Oncol. 2008. PMID: 18506025 Corrected and republished. Clinical Trial.
Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study.
Simons JP, Aaronson NK, Vansteenkiste JF, ten Velde GP, Muller MJ, Drenth BM, Erdkamp FL, Cobben EG, Schoon EJ, Smeets JB, Schouten HC, Demedts M, Hillen HF, Blijham GH, Wouters EF. Simons JP, et al. Among authors: vansteenkiste jf. J Clin Oncol. 1996 Apr;14(4):1077-84. doi: 10.1200/JCO.1996.14.4.1077. J Clin Oncol. 1996. PMID: 8648360 Clinical Trial.
Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.
Mattson K, Vansteenkiste J, Stupp R, Bargetzi M, Saarinen A, Jekunen A, Fillet G, Teixeira M, Gatzemeier U, Olivares R, Soussan-Lazard K, Bérille J. Mattson K, et al. Among authors: vansteenkiste j. Anticancer Drugs. 2000 Jan;11(1):7-13. doi: 10.1097/00001813-200001000-00002. Anticancer Drugs. 2000. PMID: 10757557 Free article. Clinical Trial.
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine.
Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL; Leuven Lung Cancer Group. Vansteenkiste JF, et al. Ann Oncol. 2001 Sep;12(9):1221-30. doi: 10.1023/a:1012208711013. Ann Oncol. 2001. PMID: 11697832 Free article. Clinical Trial.
Dose-intensified accelerated vindesine-ifosfamide-cisplatin (VIP) chemotherapy followed by high-dose accelerated hyperfractionated radiotherapy in patients with pathologically proven stage IIIB non-small cell lung cancer: a feasibility study.
De Ruysscher D, Lievens Y, Van den Brande P, Nackaerts K, Vansteenkiste J. De Ruysscher D, et al. Among authors: vansteenkiste j. Radiother Oncol. 2002 Jul;64(1):33-6. doi: 10.1016/s0167-8140(02)00144-5. Radiother Oncol. 2002. PMID: 12208572
359 results